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Abstract
Bronchiectasis is an abnormal dilatation of bronchi and bronchioles associated with repeated cycles of
airway infection and inflammation. This review will focus on non-cystic fibrosis bronchiectasis in
children, with regard to etiology, diagnosis, treatment options, and recent advances.
Introduction and context
Although the frequency of childhood bronchiectasis has
been reduced in western countries, it remains a common
problem in poorer countries and among certain demo-
graphic groups (native Alaskan children in the USA, in
Pacific Islanders, and in New Zealand Maori). Addition-
ally, non-cystic fibrosis (non-CF) bronchiectasis is now
being identified more often by high resolution com-
puted tomography (CT).
Bronchiectasis results when inflammatory and infectious
damage to the bronchial and bronchiolar walls leads to a
vicious cycle of airway injury [1] and airway and lung
parenchyma destruction [2]. Sputum analyses and
bronchial mucosal biopsy specimens from bronchiecta-
sis patients have shown increased concentrations of
elastase [3], interleukin-8 [4], tumor necrosis factor [5],
and prostanoids [6]. Hence, anatomic factors, chronic
infection and inflammation, and host defense all play
important, yet poorly understood, roles in the develop-
ment of bronchiectasis [7].
Bronchiectasis is categorized as focal or diffuse. All
patients with focal bronchiectasis require bronchoscopy
and/or high resolution CT to evaluate the airways, while
patients with diffuse bronchiectasis should be assessed
for underlying systemic abnormalities. Focal bronchiec-
tasis can be secondary to airway obstruction such as
bronchial atresia/malacia/stenosis, vascular ring/sling,
followingforeignbodyaspiration,extrinsiccompression,
airway tumors, necrotizing pneumonia, or congenital
parenchymal malformation. The etiologies of diffuse
non-CF bronchiectasis are presented in Table 1. Even
after thorough evaluation, diagnosis remains idiopathic
in the majority of patients. The relative frequency of each
etiology varies, but idiopathic, post-infectious, and
immune deficiencies are probably the commonest
etiologies.
Diagnosis and treatment
Bronchiectasis should be suspected in children who
present with chronic productive cough, airway obstruc-
tion, and recurrent infections. The diagnosis is made by
high-resolution CT scans, which can classify the bronch-
iectasisasfocalordiffuse,cylindrical,varicose,orsaccular.
Treatment goals are to reduce the number of exacerba-
tions and improve quality of life. Therapeutic strategies
are largely derived from CF. All patients with bronch-
iectasis should have a microbiological examination
(spontaneous/induced sputum or bronchoalveolar
lavage) for routine bacterial and non-tuberculosis
mycobacteria (NTM). About one-third of patients with
non-CF bronchiectasis are chronically colonized with
Pseudomonas aeruginosa.P a t i e n t sw i t hP. aeruginosa
experience an accelerated decline in lung function and
more frequent exacerbations [8]. Maintenance therapy
with inhaled tobramycin has shown a microbiological
benefit in two studies [1,9] but those studies were not
powered to detect a clinical benefit. Antimicrobial, anti-
inflammatory, airway clearance therapies, and immuni-
zation are the mainstays of therapy.
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Etiology
Common variable immunodeficiency should be con-
sidered,as the age at diagnosis shows two peaks,between
6 and 10 years of age, and in young adulthood [10].
Bare lymphocyte syndrome is an autosomal recessive
disorder [11] characterized by the absence of constitutive
and inducible expression of major histocompatibility
complex class II (MHCII) genes [12,13], which affect all
cell types. An additional immune deficiency associated
with pulmonary manifestations is that of Del-1 (devel-
opmental endothelial locus-1), which is an anti-adhesive
factorthatinterfereswithleukocyte-endothelialadhesion
dependent on the integrin lymphocyte function-asso-
ciated antigen-1 (LFA-1). Endothelial Del-1 deficiency
increases LFA-1-dependent leukocyte adhesion and
transmigration into the lungs, leading to excessive
neutrophilic lung inflammation and bronchiectasis [14].
Post-infectious bronchiectasis secondary to NTM may
occur in children with CF or HIV infection and in
middle-aged Caucasian women without pre-existing
conditions [15]. Of interest, in one study 36% of these
females carried mutations in the CF transmembrane
regulator (CFTR) gene [16].
Diagnosis
Primary ciliary diskenesia (PCD) is characterized by
bronchiectasis, rhinosinusitis, ear infections, and inferti-
lity. Approximately one-half of the patients with PCD
have situs inversus totalis or heterotaxy [17]. Eight genes
have been linked with PCD: two outer dynein arm
(ODA) genes, intermediate chain (DNAI1) and heavy
chain (DNAH5), have been found to be mutated in
approximately 30-38% of affected families [18-21].
Mutations in other ODA genes (TXNDC3 and DNAI2)
have been noted in a small fraction (approximately 2%)
of PCD patients [22]. Lately, mutations in ktu, which is
required for the dynein complex assembly, have been
described in approximately 12% of PCD patients with
defects in both the ODA and inner dynein arm (IDA)
[23]. Recently, mutations in radial spoke head protein
genes RSPH9 and RSPH4A have been shown to cause
central-microtubular-pair abnormalities in seven con-
sanguineous Pakistani families in the UK [24]. Digital
high-speed videomicroscopy has been used to detect
more subtle abnormalities in ciliary beat pattern and has
demonstrated that some of these patterns are associated
with specific ultrastructural defects: immotile or limited
flickering for ODA defects; low-amplitude stiff beat for
isolated IDA defects or radial spoke defects; and circular,
whip-like beat for central microtubular defects such as
transposition [25]. The nasal nitric oxide method was
shown to be a bona fide diagnostic test, as in PCD nasal
and exhaled nitric oxide values are lower than normal,
for reasons that are still unclear [26].
Treatment
There is no evidence base or consensus on the treatment
of non-CF bronchiectasis [27]. Anwar et al. [28] recently
reported the efficacy of long-term, oral, low-dose
Table 1. Etiologies of non-cystic fibrosis bronchiectasis
Etiology Examples Comments
Idiopathic Should be classified after a thorough evaluation
Post-infection Post measles, pertussis, adenovirus, tuberculosis Decreasing frequency in western countries. Non-
progressive bronchiectasis
Genetic disease CF, primary ciliary dyskenesia*, alfa 1 anti-trypsin (AAT)
deficiency
Atypical CF has been increasingly recognized. AAT
causes bronchiectasis only in adulthood
Aspiration/gastroesophageal reflux Impaired gag reflex, impaired esophageal motility,
esophageal atresia + fistula, convulsions, cleft palate
Barium swallow, pH metry, and swallowing mechanisms
should be evaluated
Immune deficiency Severe combined immune deficiency, Omenn’s syn-
drome, hypogammaglobulinemia, hyper-IgE chronic
granulomatous disease, common variable hypogamma*,
ataxia telangiectasia, bare lymphocyte syndrome*,
DEL1*, Wiskott-Aldrich syndrome, HIV, immunosup-
pressive treatment [corticosteroids, irradiation, organ
and bone marrow transplants, biologic agents
(for example, infliximab, etanercept)]
This group has increased due to descriptions of new
immune deficiencies and increased iatrogenic immuno-
deficiency. Refer for immunological evaluation
Collagen vascular disorders Systemic lupus erythematosus, rheumatoid arthritis
Inflammatory bowel diseases Ulcerative colitis, Crohn’s disease
Miscellaneous Sarcoidosis, Young syndrome, Mounier-Kuhn
syndrome, Ehler-Danlos syndrome, Marfan
syndrome, yellow nail syndrome
ABPA CF, asthma New treatment options*
*See text for recent advances. AAT, alfa 1 anti-trypsin; ABPA, allergic bronchopulmonary aspergillosis; CF, cystic fibrosis; DEL-1, developmental endothelial
locus-1.
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ficial effects were demonstrated on exacerbation fre-
quency, sputum microbiology, FEV1 (forced expiratory
volume in 1 second) testing, and sputum volume. This
therapy was recommended for the management of
difficult-to-control bronchiectasis. The mechanism of
action of azithromycin is not fully elucidated, but studies
suggest potential immunomodulatory effects. Azithro-
mycin significantly reduces bronchoalveolar lavage
neutrophilia and interleukin-8 mRNA [29]. It is also
known to have prokinetic effects on the gut and has been
associated with lower levels of aspiration markers. The
anti-pseudomonal effect of azithromycin may represent
an inhibitory effect on quorum sensing (a phenomenon
whereby the accumulation of signaling molecules
enables a single cell to sense the number of bacteria
according to the local density of their population),
biofilm formation, production of immunostimulatory
exoproducts, and the inflammatory response to this
organism [30].
There is an ongoing debate about the efficacy of inhaled
corticosteroids in CF and non-CF bronchiectasis [31].
Mucoactive agents such as hypertonic saline 7% are
beneficial in patients with CF [32]. Few reports are
available on hypertonic saline in non-CF bronchiectasis.
Mannitol in a dry powder inhaler has been used as a
hyperosmolar stimulus to increase mucociliary clearance
in bronchiectatic subjects [33].
Two case reports documented the usefulness of short-
term use of dornase alfa in treating PCD [34]. As DNAH5
mutations in PCD patients are nonsense mutations,
pharmacogenetic therapies such as PTC124 that are
designed to read through premature stop codons may
potentially correct the primary defect in these PCD
patients.
Allergic bronchopulmonary aspergillosis (ABPA) treat-
ment involves long-term attenuation of the inflamma-
tory and immunological activity with corticosteroids and
reduction of the antigen burden from fungal coloniza-
tion with antifungal agents. High-dose intravenous pulse
methylprednisolone was found to be an effective
treatment for ABPA in CF with relatively minor side
effects [35]. Omalizumab, a humanized monoclonal
antibody directed against IgE, has a potential role as
adjuvant therapy for CF patients that are corticosteroid-
dependent [36].
Prognosis
Lung function usually stabilizes in children with non-CF
bronchiectasis [27] if diagnosed early and a consequent
long-term treatment plan is followed. Surgery and lung
transplantation are rarely required for non-CF
bronchiectasis.
Implications for clinical practice
Non-CF bronchiectasis in childhood is still a common
cause of childhood morbidity. Identifying and treating
the underlying disease is essential to prevent the
progression of bronchiectasis. New diagnostic tools
such as the nasal nitric oxide test, immunological tests
for bare lymphocyte syndrome and DEL-1, and culture
for NTM, may aid in specific diagnosis. Therapeutic
strategies are largely derived from CF bronchiectasis and
include antimicrobial, anti-inflammatory, and airway
clearance therapies, and immunization. Pulse steroids
and omalizumab may offer a better control for ABPA.
Azithromycin, as an immuno-modulator agent, should
be considered in patients with severe bronchiectasis. The
role of new mucoactive agents should be further
explored.
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